<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928135</url>
  </required_header>
  <id_info>
    <org_study_id>200901713</org_study_id>
    <nct_id>NCT00928135</nct_id>
  </id_info>
  <brief_title>Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects</brief_title>
  <official_title>Randomized Controlled Study of Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Hospitalized Patients With Exacerbation of Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Zabner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis (CF) lung disease is characterized by chronic bacterial colonization and&#xD;
      recurrent infection of the airways. Lowering the airway surface liquid (ASL) salt&#xD;
      concentration has been shown to increase activity of salt sensitive antimicrobial peptides.&#xD;
&#xD;
      Xylitol is a 5-carbon sugar that can lower the ASL salt concentration, thus enhancing innate&#xD;
      immunity. In this study, the investigators propose to test the safety and tolerability of&#xD;
      aerosolized xylitol used daily for 2 weeks in subjects with cystic fibrosis. In a pilot,&#xD;
      2-week study, 60 subjects with cystic fibrosis with an FEV1(Forced expiratory volume in 1&#xD;
      second ) &gt;30% predicted will be randomized to receive aerosolized 7% hypertonic saline (5 ml)&#xD;
      or 15% xylitol, (5 ml) twice a day for 14 days. The primary outcomes will be safety as&#xD;
      assessed by FEV1 change from baseline, adverse events and respiratory symptom score. Outcomes&#xD;
      for trend in efficacy include density of colonization of sputum, time to next exacerbation,&#xD;
      sputum cytokines and revised CF quality of life questionnaire.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CF) lung disease is characterized by chronic bacterial colonization and&#xD;
      recurrent infection of the airways. Disruption of the cystic fibrosis transmembrane&#xD;
      conductance regulator chloride channels in subjects with CF results in altered fluid and&#xD;
      electrolyte transport across the airway epithelium thereby initiating infections.&#xD;
&#xD;
      These infections eventually destroy the lungs and contribute to significant morbidity and&#xD;
      mortality in patients with CF. It is well known that antibacterial activity of innate immune&#xD;
      mediators such as lysozyme and beta defensins in human airway surface liquid (ASL) is&#xD;
      salt-sensitive; an increase in salt concentration inhibits their activity.&#xD;
&#xD;
      Conversely, their activity is increased by low ionic strength. Lowering the ASL salt&#xD;
      concentration and increasing the ASL volume might therefore potentiate innate immunity and&#xD;
      therefore decrease or prevent airway infections in subjects with CF.&#xD;
&#xD;
      Xylitol, a five-carbon sugar with low transepithelial permeability, which is poorly&#xD;
      metabolized by bacteria can lower the salt concentration of both cystic fibrosis (CF) and&#xD;
      non-CF epithelia in vitro. Xylitol is an artificial sweetener that has been successfully used&#xD;
      in chewing gums to prevent dental caries; it has been used as an oral sugar substitute&#xD;
      without significant adverse effects. It has also been shown to decrease the incidence of&#xD;
      acute otitis media by 20-40%; nasal application to normal human subjects was found to&#xD;
      decrease colonization with coagulase negative staphylococcus. We found that aerosolized&#xD;
      iso-osmolar xylitol was safe in mice, healthy volunteers and stable subjects with CF when&#xD;
      administered over a single day. In a recent study, we observed that single doses of 10%&#xD;
      followed by 15% xylitol was well tolerated by subjects with cystic fibrosis who were stable.&#xD;
      In this pilot study we propose to test the hypothesis that aerosolized hypertonic xylitol&#xD;
      given daily for 2 weeks, will be safe and well tolerated and potentially lower the density of&#xD;
      colonization in subjects with CF compared to hypertonic saline. We chose hypertonic&#xD;
      concentration of xylitol to be comparable in part to hypertonic saline which is being offered&#xD;
      as a routine treatment in hospitalized patients with CF exacerbation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2013</start_date>
  <completion_date type="Actual">April 9, 2018</completion_date>
  <primary_completion_date type="Actual">April 9, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1 Percentage Predicted From Baseline</measure>
    <time_frame>14 days</time_frame>
    <description>Change in lung function (forced expiratory volume in 1 second) between baseline and Day 14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Density of Colonization of Pseudomonas Aeruginosa Per Gram of Sputum</measure>
    <time_frame>14 days</time_frame>
    <description>Mean difference from baseline of Sputum density expressed as log colony forming units between baseline and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbations During 6 Months Follow-up</measure>
    <time_frame>6 months</time_frame>
    <description>numbers of subjects that experienced an exacerbation during the 6 months follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>7% Hypertonic saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 ml of 7% saline twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic xylitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 ml of 15% xylitol twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xylitol</intervention_name>
    <description>15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
    <arm_group_label>Hypertonic xylitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline</intervention_name>
    <description>7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
    <arm_group_label>7% Hypertonic saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with CF (medical record evidence of CFTR(Cystic fibrosis transmembrane&#xD;
             conductance regulator) mutation or sweat chloride test or nasal voltage difference,&#xD;
             and 1 or more clinical findings of CF),&#xD;
&#xD;
          -  Age 12 or greater&#xD;
&#xD;
          -  FEV1 &gt; 30% predicted(within the last 14 days and oxygen saturation &gt; 90% on&#xD;
             FiO2(fraction of inspired oxygen) â‰¤ 50%,&#xD;
&#xD;
          -  Admitted for an exacerbation,&#xD;
&#xD;
          -  Use of effective contraception in women,&#xD;
&#xD;
          -  Able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy,&#xD;
&#xD;
          -  History of asthma based on methacholine challenge or bronchial hyperresponsiveness on&#xD;
             PFTS(Pulmonary Function Test),&#xD;
&#xD;
          -  Hemoptysis more than 60 mL within the last 30 days,&#xD;
&#xD;
          -  Use of any investigational study drug within the last 30 days,&#xD;
&#xD;
          -  Initiation of hypertonic saline within the last 30 days,&#xD;
&#xD;
          -  A serum creatinine 2 mg/dl or more&#xD;
&#xD;
          -  Active malignancy in the last year&#xD;
&#xD;
          -  Antibiotics for CF exacerbation as an outpatient in the last 2 weeks&#xD;
&#xD;
          -  B cepacia colonization&#xD;
&#xD;
          -  Waiting list for lung transplant&#xD;
&#xD;
          -  Lack of FEV1 data from the last 14 days&#xD;
&#xD;
          -  Previous participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Zabner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMID: 16781897</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lakshmi Durairaj, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>PMID: 16781897</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan L Launspach, R.N., CCRC</last_name>
    <role>Study Chair</role>
    <affiliation>PMID: 16781897</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Durairaj L, Launspach J, Watt JL, Mohamad Z, Kline J, Zabner J. Safety assessment of inhaled xylitol in subjects with cystic fibrosis. J Cyst Fibros. 2007 Jan;6(1):31-4. Epub 2006 Jun 15.</citation>
    <PMID>16781897</PMID>
  </reference>
  <reference>
    <citation>Durairaj L, Neelakantan S, Launspach J, Watt JL, Allaman MM, Kearney WR, Veng-Pedersen P, Zabner J. Bronchoscopic assessment of airway retention time of aerosolized xylitol. Respir Res. 2006 Feb 16;7:27.</citation>
    <PMID>16483382</PMID>
  </reference>
  <reference>
    <citation>Brown CL, Graham SM, Cable BB, Ozer EA, Taft PJ, Zabner J. Xylitol enhances bacterial killing in the rabbit maxillary sinus. Laryngoscope. 2004 Nov;114(11):2021-4.</citation>
    <PMID>15510034</PMID>
  </reference>
  <reference>
    <citation>Durairaj L, Launspach J, Watt JL, Businga TR, Kline JN, Thorne PS, Zabner J. Safety assessment of inhaled xylitol in mice and healthy volunteers. Respir Res. 2004 Sep 16;5:13.</citation>
    <PMID>15377394</PMID>
  </reference>
  <reference>
    <citation>Zabner J, Seiler MP, Launspach JL, Karp PH, Kearney WR, Look DC, Smith JJ, Welsh MJ. The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing. Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11614-9.</citation>
    <PMID>11027360</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 18, 2009</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>October 27, 2020</results_first_submitted>
  <results_first_submitted_qc>June 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2021</results_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Joseph Zabner</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT00928135/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>subject screen failed due to intolerance to hypertonic saline&#xD;
subjects failed xylitol trial inhalation</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>7% Hypertonic Saline</title>
          <description>5 ml of 7% saline twice daily&#xD;
Saline: 7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
        </group>
        <group group_id="P2">
          <title>Hypertonic Xylitol</title>
          <description>5 ml of 15% xylitol twice daily&#xD;
Xylitol: 15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hypertonic Saline</title>
          <description>7% hypertonic saline given twice daily for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Xylitol</title>
          <description>Xylitol given twice daily for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.4" spread="12.8"/>
                    <measurement group_id="B2" value="29.7" spread="12.3"/>
                    <measurement group_id="B3" value="30.1" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory volume % predicted</title>
          <units>Percentage predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="18.8"/>
                    <measurement group_id="B2" value="58.8" spread="20.1"/>
                    <measurement group_id="B3" value="56.1" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in FEV1 Percentage Predicted From Baseline</title>
        <description>Change in lung function (forced expiratory volume in 1 second) between baseline and Day 14</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>7% Hypertonic Saline</title>
            <description>5 ml of 7% saline twice daily&#xD;
Saline: 7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Xylitol</title>
            <description>5 ml of 15% xylitol twice daily&#xD;
Xylitol: 15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1 Percentage Predicted From Baseline</title>
          <description>Change in lung function (forced expiratory volume in 1 second) between baseline and Day 14</description>
          <units>percentage of predicted</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="8.1" upper_limit="15.5"/>
                    <measurement group_id="O2" value="8.8" lower_limit="4.7" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Density of Colonization of Pseudomonas Aeruginosa Per Gram of Sputum</title>
        <description>Mean difference from baseline of Sputum density expressed as log colony forming units between baseline and Day 14</description>
        <time_frame>14 days</time_frame>
        <population>Subjects who were able to produce sputum at baseline and day 14</population>
        <group_list>
          <group group_id="O1">
            <title>7% Hypertonic Saline</title>
            <description>5 ml of 7% saline twice daily&#xD;
Saline: 7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Xylitol</title>
            <description>5 ml of 15% xylitol twice daily&#xD;
Xylitol: 15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Colonization of Pseudomonas Aeruginosa Per Gram of Sputum</title>
          <description>Mean difference from baseline of Sputum density expressed as log colony forming units between baseline and Day 14</description>
          <population>Subjects who were able to produce sputum at baseline and day 14</population>
          <units>log CFU/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-2.8" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-2.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exacerbations During 6 Months Follow-up</title>
        <description>numbers of subjects that experienced an exacerbation during the 6 months follow-up</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>7% Hypertonic Saline</title>
            <description>5 ml of 7% saline twice daily&#xD;
Saline: 7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Xylitol</title>
            <description>5 ml of 15% xylitol twice daily&#xD;
Xylitol: 15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbations During 6 Months Follow-up</title>
          <description>numbers of subjects that experienced an exacerbation during the 6 months follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the duration of the study treatment (up tp 14 days) and Up to 7 days after last study drug inhalation for a total of up to 21 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>7% Hypertonic Saline</title>
          <description>5 ml of 7% saline twice daily&#xD;
Saline: 7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
        </group>
        <group group_id="E2">
          <title>Hypertonic Xylitol</title>
          <description>5 ml of 15% xylitol twice daily&#xD;
Xylitol: 15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Distal intestinal obstruction syndrome</sub_title>
                <description>DIOS is a common problem among CF patients and was deemed unrelated to the study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>abnormal laboratory values</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>abnormal liver function tests</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>bronchospasm</sub_title>
                <description>wheezing</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>flu</sub_title>
                <description>Influenza like illness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lakshmi Durairaj</name_or_title>
      <organization>University of Iowa</organization>
      <phone>3193537968</phone>
      <email>lakshmi-durairaj@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

